This page contains a Flash digital edition of a book.
laboratory informatics Change and continuity


Wilkie looks at the case of Abbott Informatics and Starlims


What happens when a relatively small informatics company is acquired by a very large healthcare corporation? Tom


Dubai earlier in the week. But for all the strain of a jet-setting lifestyle, in an interview with Scientific Computing World he was very upbeat about the benefits that have followed Abbott, a global healthcare company, acquiring Starlims in 2009. Initially, the consequences of being taken


S


over were fairly minimal and, ‘in terms of the effect on our customers, there actually weren’t any,’ he said. One of the advantages, he continued, of Abbott being a healthcare company is that ‘they have encouraged us to look much more at the healthcare informatics market. Tey are a very large company, and this gives us financial security and the ability to go and invest in the development of new products – specifically our healthcare informatics product.’ In the past, the healthcare informatics


market and the traditional LIMS market have been very separate. Even the acronyms were different: companies selling to hospitals provided LIS (laboratory information systems) and they tended not to compete with suppliers of LIMS (laboratory information management systems). But geography plays an important role in


such markets. Wood explained: ‘Te emphasis to begin with is in developing a system for the UK and European market – on the needs of the UK National Health Service (NHS) and other European government-funded healthcare systems. We recruited some people with expertise in that area to help us with the development.’ Te expectation is that once a system has


12 SCIENTIFIC COMPUTING WORLD


imon Wood, general manager for EMEA informatics for Abbott, was packing for a two-week trip to the USA, having only returned from


been built to meet the needs of the European markets, it will be possible can expand to other regions. But there are already benefits to the business in related areas, according to Wood: ‘We do play in the kind of commercial reference labs that do specialist clinical testing’. In those organisations, the progress in terms of market share has already been global. In the healthcare arena, ‘the key thing that


we’re aſter is how do we differentiate ourselves from those established players all of whom have been in the market for a significant


ABBOTT HOPES TO


CHANGE THE MODEL OF IMPLEMENTING THE SYSTEM


amount of time now? We are really looking at bringing in our much more modern technology to meet the needs of customers.’ Abbott hopes to change the model of


implementing the system, so it becomes easier to configure and eases the task of upgrading, taking advantage of the latest technology and porting data, some of which, given the clinical setting, may have been around for up to 20 years. Wood said: ‘We have a development team in the UK who are dedicated to this but we also have people in the US working on the system.’ It is a joint development between the two groups and the customer. Healthcare is seen as an expansion that will not divert focus from the existing client


base. ‘Te idea is that the basic technology that underlies our system will be the same for all customers,’ Wood explained. ‘We sell it as a three-layer technology, where we have the underlying technology and that supports everything else. On top of that we have the applications: for the healthcare market; for the quality manufacturing market –pharmaceutical manufacturing, the oil refineries, etc. We have a system that’s used in the forensics market, and there is one for environmental as well. All of those will have their own teams looking at development of the application and all of those teams use the basic underlying technology. Te third layer is using the applications to create the data that is used to run your lab what the customer does on a day-to-day basis.’ In the traditional areas, ‘we will continue


to serve our existing customer base. Tere will be new opportunities which will come up, particularly among smaller specialist labs. Tey don’t have a lot of resources; they don’t want to have an IT infrastructure; and there our cloud offering can be something that can be an advantage to them. Tey get the benefits of a LIMS, but they do not have a box in the corner that they don’t know what to do with.’ From the oil industry to pharmaceuticals,


markets have become more competitive – and these external pressures are in turn forcing change on the analytical laboratories and on the informatics systems that they use. Te acquisition has made possible a strategy that embraces both change and continuity.


@scwmagazine l www.scientific-computing.com


Starlims


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41